Business
NEOGEN® and Gencove Launch InfiniSEEK™ -- The First Whole Genome and Genotyping Sequencing Solution for Cattle Breeders
InfiniSEEK's unique technology enables simultaneous low-pass whole genome sequencing and high-coverage genotyping at regions of interest. LINCOLN, Neb. and
About this update from Neogen Corporation
[{"type":"text","content":"InfiniSEEK's unique technology enables simultaneous low-pass whole genome sequencing and high-coverage genotyping at regions of interest.\n LINCOLN, Neb. and NEW YORK, May 12, 2022 /PRNewswire/ -- NEOGEN® Corporation (NASDAQ: NEOG) and Gencove, the leading low-pass whole genome sequencing and analysis software company, today announced the launch of InfiniSEEK™, an innovative, cost-effective solution for whole genome sequencing and targeted SNP analysis.\nCombining NEOGEN's world-class genomic solutions and services with Gencove's low-pass sequencing and analytics software, the solution can deliver genomic insights to help advance cattle breeding programs worldwide.\n\"NEOGEN offers innovative, high quality, value-added genomic technologies to the agrigenomics industry,\" said Dr. Jason Lilly, NEOGEN's Vice President of International Business. \"With the launch of InfiniSEEK, our customers now have a data-rich, cost-efficient way to get genome-wide sequence data, specific genetic traits, and parentage markers simultaneously with excellent accuracy to characterize cattle across the world. We are excited to add this new solution to NEOGEN's portfolio.\"\n\"Gencove developed a process that simultaneously yields low-pass whole genome sequencing and high coverage genotyping at pre-selected loci in a single molecular reaction,\" said Dr. Joseph Pickrell, co-founder and CEO of Gencove. \"InfiniSEEK is NEOGEN's first commercial product built on the Gencove software and analysis platform, and we are thrilled it will be deployed through NEOGEN's best in class genomics offering services.\"\nWith InfiniSEEK, the industry now has a platform to:\nMinimize selection bias by sequencing more or all of a populationDiscover new traits impacting desired phenotypesReliably manage more than 400 bovine genetic traits and conditionsInfiniSEEK has been rigorously validated, and results demonstrate low-pass genome-wide sequencing to be greater than 99 percent concordant to deep whole-genome sequencing and can offer even higher, clinical-grade accuracy at specific regions of interest.\nAbout GencoveWith additional opportunities to improve human health and the challenge of feeding the world's growing population, demand for genomic information has skyrocketed. To meet the need, Gencove combines low-pass whole genome sequencing (reading the DNA at shallower d...